Abstract
A number of urea derivatives were synthesized and screened for their urease and α-chymotrypsin inhibition effects, whereby one of the compounds, N-4-nitrophenyl-N’-4’-nitrophenylurea (3), showed strong urease inhibition (IC50 = 1.25μM). We found that the same compound is also an efficient α-chymotrypsin inhibitor having an IC50 value of 3.15μM.
Keywords: Urease, α-chymotrypsin, Urea derivatives
Letters in Drug Design & Discovery
Title: Urease and α-Chymotrypsin Inhibitory Effects of Selected Urea Derivatives
Volume: 5 Issue: 6
Author(s): Shahnaz Perveen, Khalid Mohammed Khan, Muhammad Arif Lodhi, Muhammad Iqbal Choudhary, Atta-ur-Rahman and Wolfgang Voelter
Affiliation:
Keywords: Urease, α-chymotrypsin, Urea derivatives
Abstract: A number of urea derivatives were synthesized and screened for their urease and α-chymotrypsin inhibition effects, whereby one of the compounds, N-4-nitrophenyl-N’-4’-nitrophenylurea (3), showed strong urease inhibition (IC50 = 1.25μM). We found that the same compound is also an efficient α-chymotrypsin inhibitor having an IC50 value of 3.15μM.
Export Options
About this article
Cite this article as:
Perveen Shahnaz, Khan Mohammed Khalid, Lodhi Arif Muhammad, Choudhary Iqbal Muhammad, Atta-ur-Rahman and Voelter Wolfgang, Urease and α-Chymotrypsin Inhibitory Effects of Selected Urea Derivatives, Letters in Drug Design & Discovery 2008; 5 (6) . https://dx.doi.org/10.2174/157018008785777315
DOI https://dx.doi.org/10.2174/157018008785777315 |
Print ISSN 1570-1808 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-628X |
Related Journals
Related Books
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
The Coronin Family and Human Disease
Current Protein & Peptide Science Decreased Serum Adiponectin Level Affected Clinical Pathological Characteristics of Patients with Gastric Cancer
Current Proteomics Nitric Oxide in Cancer Therapeutics: Interaction with Cytotoxic Chemotherapy
Current Pharmaceutical Design MicroRNAs in Glioblastoma: Role in Pathogenesis and Opportunities for Targeted Therapies
CNS & Neurological Disorders - Drug Targets Crosstalk between IGF-1R and other Tumor Promoting Pathways
Current Pharmaceutical Design Tyrosine Kinase Inhibitors: A Potential Approach to the Treatment of Hepatocellular Carcinoma
Current Pharmaceutical Design BCR/ABL1 Fusion Transcripts Generated from Alternative Splicing: Implications for Future Targeted Therapies in Ph+ Leukaemias
Current Molecular Medicine Axin PPI Networks: New Interacting Proteins and New Targets?
Current Topics in Medicinal Chemistry The Role of CXC-Chemokine IL-8, IL-6 and CXCR2 Receptor in Lymphoplasmacytic Lymphoma: Correlations with Microvascular Characteristics and Clinical Features
Current Angiogenesis (Discontinued) Protein Interaction Domains: Structural Features and Drug Discovery Applications (Part 2)
Current Medicinal Chemistry Resveratrol in Cancer: Cellular and Mitochondrial Consequences of Proton Transport Inhibition
Current Pharmaceutical Design The PA207 Peptide Inhibitor of LIM-only Protein 2 (Lmo2) Targets Zinc Finger Domains in a Non-specific Manner
Protein & Peptide Letters Recent Advances in the Development of Selective Mcl-1 Inhibitors for the Treatment of Cancer (2017-Present)
Recent Patents on Anti-Cancer Drug Discovery Antioxidant Potential of Solvent Partitioned Extraction from Aqueous Extract of Gracilaria Tenuistipitata
Current Organic Chemistry Design and Synthesis of Novel Antineoplastic Agents Inspired from Marine Bromopyrrole Alkaloids
Anti-Cancer Agents in Medicinal Chemistry Antagonists of CCR4 as Immunomodulatory Agents
Current Topics in Medicinal Chemistry Roles of EGFR, PI3K, AKT, and mTOR in Heavy Metal-Induced Cancer
Current Cancer Drug Targets Patent Selections:
Recent Patents on Anti-Cancer Drug Discovery Pharmacology and Therapeutic Applications of Enediyne Antitumor Antibiotics
Current Molecular Pharmacology ERGIC3 Silencing Additively Enhances the Growth Inhibition of BFA on Lung Adenocarcinoma Cells
Current Cancer Drug Targets